Previous 10 | Next 10 |
Nemaura (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs. The company today announced the close of its registered direct offering with two health care-focused...
LOUGHBOROUGH, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight redu...
Nemaura Medical ( NASDAQ: NMRD ) shares dropped 41% premarket on Friday after the medical technology company priced a ~$8.4M securities offering . The offering comprises 4,796,206 shares of common stock, issued in a registered direct offering, and warrants to purchase up to 4,...
LOUGHBOROUGH, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight redu...
Nemaura Medical (NASDAQ: NMRD) , a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, has received a purchase order from HealthFleet Inc., a leading telehealth provider...
Nemaura to integrate its proBEAT TM glucose sensors with HealthFleet’s proven RestoreHealth wellness program targeted at U.S. market LOUGHBOROUGH, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Co...
MedTech company Nemaura Medical ( NASDAQ: NMRD ) announced results from a study for its Miboko metabolic health program on Tuesday, indicating that all participants in an initial study group experienced weight loss. The Miboko program requires a daily-wear non-invasive glucose sensor ...
A verage weight loss of 3.7 pounds and an average BMI reduction of 0.6 after 10 weeks in initial patients LOUGHBOROUGH, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc . (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical ...
Nemaura (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs. The company today announced that its CEO Dr. Faz Chowdhury will present a corporate overvi...
Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, announces that CEO D...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Maxim Group LLC, a full-service investment banking, securities and wealth management firm, and M-Vest, a digital community built for issuers, investors, and thought leaders, present the 2024 Healthcare IT Virtual Conference. The conference will take pla...
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will imp...
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel gr...